NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
57 trialsNCT04030455 2026-03-09
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00588770 2026-03-03
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02031250 2026-03-02
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03040999 2026-02-04
KEYNOTE-412
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01302834 2026-01-12
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03358472 2025-12-03
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Phase 3 Completed
NCT04854499 2025-11-19
ELEVATE HNSCC
Gilead Sciences
Phase 2 Terminated
NCT04459715 2025-10-08
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
EMD Serono
Phase 3 Terminated
NCT00665392 2025-08-01
ECHO-07
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Completed
NCT03944915 2025-05-11
DEPEND
University of Chicago
Phase 2 Completed
NCT03107182 2025-05-06
OPTIMA-II
University of Chicago
Phase 2 Completed
NCT03389477 2025-04-13
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT01898494 2025-02-28
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT00544414 2025-02-19
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
City of Hope Medical Center
Phase 2 Completed
NCT04649476 2025-01-10
NEOPBOSCC
Hospital of Stomatology, Wuhan University
Phase 2 Completed
NCT02281955 2025-01-07
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02573493 2024-12-27
APA
Washington University School of Medicine
Phase 2 Completed
NCT01530997 2024-11-13
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT02777385 2024-08-01
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT01064479 2024-07-16
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02072148 2024-05-06
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Icahn School of Medicine at Mount Sinai
Phase NA Completed
NCT03077243 2024-05-02
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01588431 2024-02-14
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT00820248 2023-08-22
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00047008 2023-07-07
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00096174 2023-06-29
Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01084083 2023-06-28
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01088802 2022-11-08
Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03502148 2022-10-21
PRV111
Privo Technologies
Phase 1/2 Completed
NCT01265849 2022-08-19
IT-MATTERS
CEL-SCI Corporation
Phase 3 Completed
NCT00265941 2022-06-14
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00566540 2021-11-26
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT03349710 2021-08-09
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT02177838 2021-04-21
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Rutgers, The State University of New Jersey
Phase NA Terminated
NCT00736944 2020-09-09
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00851877 2020-08-21
Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT00721513 2020-04-07
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT01836029 2019-10-29
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Celgene
Phase 2 Completed
NCT00882583 2019-01-09
Dasatinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT00084318 2018-12-12
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00756444 2018-11-15
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Amgen
Phase 2 Completed
NCT01732640 2018-07-26
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT00352118 2017-12-28
Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01221753 2017-12-06
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00400205 2017-11-06
Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil
Emory University
Phase 2 Terminated
NCT00423930 2017-08-18
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00895245 2017-05-18
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
University of Washington
Phase 2 Terminated